Biohaven (BHVN) Liabilities and Shareholders Equity (2021 - 2026)

Biohaven has reported Liabilities and Shareholders Equity for 6 years, with the latest figure at $466.4 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 1.63% year-over-year to $466.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.9 billion (down 13.37% YoY) and the FY2025 annual result came in at $451.4 million, down 26.61% from the prior year.
• Liabilities and Shareholders Equity improved to $466.4 million in Q1 2026 per BHVN's latest filing, from $451.4 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $661.8 million in Q4 2022 and troughed at $135.6 million in Q3 2022.
• A 5-year average of $485.5 million and a median of $506.7 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2022 and 2024: Liabilities and Shareholders Equity jumped 365.84% in 2022, then tumbled 32.33% in 2024.
• Over 5 years, Liabilities and Shareholders Equity stood at $661.8 million in 2022, then fell by 22.45% to $513.2 million in 2023, then climbed by 19.85% to $615.1 million in 2024, then decreased by 26.61% to $451.4 million in 2025, then gained by 3.31% to $466.4 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $466.4 million, $451.4 million, and $409.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.